Last reviewed · How we verify
MPI INDIUM DTPA IN 111 (INDIUM IN-111 PENTETATE DISODIUM)
MPI INDIUM DTPA IN 111 (generic name: INDIUM IN-111 PENTETATE DISODIUM) is a drug developed by GE HEALTHCARE. It is currently FDA-approved.
MPI INDIUM DTPA IN 111 is a small molecule diagnostic agent. It is used as a synonym for other compounds, including Indium (111 In) Disodium Pentetate.
At a glance
| Generic name | INDIUM IN-111 PENTETATE DISODIUM |
|---|---|
| Sponsor | GE HEALTHCARE |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Vomiting
- Skin reactions
Serious adverse events
- Death
- Septic meningitis
- Aseptic meningitis
- Pyrogenic reactions
Key clinical trials
- Advanced Diffusion Imaging in Renal Cancer Patients: Oncologic Control and Renal Functional Reserve (NA)
- Phase 1 Study Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA (Phase 1)
- A First-in-Human Dose-Finding Phase I Study of Bone-targeted High Specific Activity Stannic-117m Pentatate (Sn-117m-DTPA) in Solid Tumors With Skeletal Metastases (Phase 1)
- Investigator Initiated Investigational New Drug Application to Study the Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease (Phase 1)
- Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Ly (Phase 1)
- A Single Arm Phase II Study of Bone-Targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer With Skeletal Metastases (Phase 2)
- Pulmonary Functional Imaging for Radiation Treatment Planning (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPI INDIUM DTPA IN 111 CI brief — competitive landscape report
- MPI INDIUM DTPA IN 111 updates RSS · CI watch RSS
- GE HEALTHCARE portfolio CI
Frequently asked questions about MPI INDIUM DTPA IN 111
What is MPI INDIUM DTPA IN 111?
MPI INDIUM DTPA IN 111 (INDIUM IN-111 PENTETATE DISODIUM) is a pharmaceutical drug developed by GE HEALTHCARE.
Who makes MPI INDIUM DTPA IN 111?
MPI INDIUM DTPA IN 111 is developed and marketed by GE HEALTHCARE (see full GE HEALTHCARE pipeline at /company/ge-healthcare).
What is the generic name of MPI INDIUM DTPA IN 111?
INDIUM IN-111 PENTETATE DISODIUM is the generic (nonproprietary) name of MPI INDIUM DTPA IN 111.
What development phase is MPI INDIUM DTPA IN 111 in?
MPI INDIUM DTPA IN 111 is FDA-approved (marketed).
What are the side effects of MPI INDIUM DTPA IN 111?
Common side effects of MPI INDIUM DTPA IN 111 include Vomiting, Skin reactions. Serious adverse events: Death, Septic meningitis, Aseptic meningitis, Pyrogenic reactions.
Related
- Manufacturer: GE HEALTHCARE — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing